SCHEMBL6298331

SCHEMBL6298331

CC(C)(C)c1ccc(C(=O)O)cc1C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 4/20 0.46
RARG P13631 4/20 0.46
RARA P10276 3/20 0.44
TTR P02766 2/20 0.44
RXRA P19793 2/20 0.43
RXRB P28702 2/20 0.43
RXRG P48443 2/20 0.43
SRD5A2 P31213 4/20 0.43
P4HB P07237 1/20 0.43
KIF11 P52732 1/20 0.42
NOTUM Q6P988 1/20 0.42
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
APEX1 P27695 1/20 0.42
KMT2A Q03164 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
ACE2 Q9BYF1 1/20 0.42
ADH5 P11766 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31319449 0.88 RXRA (0.48) TTRRXRARXRBRXRGSRD5A2
SCHEMBL13653068 0.88 RARB (0.51) RARBRARGRARARXRARXRB
SCHEMBL827082 0.88 RXRA (0.48) TTRRXRARXRBRXRGSRD5A2
SCHEMBL16951924 0.83 KIF11 (0.40) RARBRARGRARATTRRXRA
SCHEMBL16958884 0.81 MAPT (0.38) KIF11NOTUMMEN1KMT2ASMN1; SMN2
SCHEMBL16957873 0.81 KIF11 (0.41) RARBRARGRARAKIF11NOTUM
SCHEMBL23699518 0.81 RARG (0.49) RARBRARGRARARXRARXRB
SCHEMBL30182007 0.79 TSHR (0.47) RARBTTRRXRARXRBRXRG
SCHEMBL312837 0.79 TSHR (0.47) RARBTTRRXRARXRBRXRG
SCHEMBL374174 0.79 TAS2R14 (0.50) RARBTTRRXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6841560-B2 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. (GB) 2005-01-11 US disclosed
US-20040209912-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2004-10-21 US disclosed
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders SMITHKLINE BEECHAM P.L.C. 2003-07-31 US disclosed
US-6245778-B1 1,6-naphthyridine anti-convulsants SMITHKLINE BEECHAM P.L.C. (GB) 2001-06-12 US disclosed
EP-0986559-A1 1,6-NAPHTHYRIDINE ANTI-CONVULSANTS SMITHKLINE BEECHAM PLC (GB) 2000-03-22 EP disclosed
WO-1998054184-A1 1,6-NAPHTHYRIDINE ANTI-CONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1998-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209912-A1 Substituted isoquinoline derivatives and their use as anticonvulsants INA, GRIN2C, GRIN2A RARB 2630/4885RARG 2641/4885RARA 2996/4885
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders PNMT, SLC6A2, GABBR1 RARB 1488/4885RARG 2430/4885RARA 1797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.